Patients with moderate kidney disease (eGFR 30-60) may use GLP-1 medications with careful monitoring, but severe kidney disease (eGFR below 30) makes compounded semaglutide inappropriate
When you eat less, your body has fewer calories coming in as an energy source, which can lead to fatigue
In people with type 2 diabetes, the glucose reduction can be rapid early in treatment or after dose escalation
It enhances mental clarity to improve focus and decrease brain fog
We determine eligibility for weight loss prescriptions based on the latest clinical guidelines for patients with obesity or who are overweight with weight-related conditions
To view or add a comment, sign in For nearly a decade, Oregon Health & Science University (OHSU) researchers have been exploring the potential of a custom-engineered molecule derived from plants that could significantly improve survival rates for an aggressive form of breast cancer, as well as for breast cancer patients with metabolic disease, such as diabetes